Micro- and macroelemental composition and safety evaluation of the nutraceutical Moringa oleifera leaves.
Moringa oleifera Lam. found in most parts of Ghana belongs to the monogenetic family Moringaceae (order Brassicales). It is a plant that has multipurpose, nonmedicinal, and medicinal uses. Its nonmedical uses include use of the seeds in wastewater treatment due to their coagulant properties [1, 2]. Its medicinal uses stem from the fact that the entire plant has high protein, vitamins, mineral, and carbohydrate content. It is, thus, of high nutritional value for both humans and livestock. Moringa leaves are rich in minerals such as iron, potassium, and calcium as well as vitamins, essential amino acids, and a number of glycosides [3, 4]. The seeds have high content (42%) of edible oil that also has medicinal uses.
Moringa is used for the management of various ailments, as a galactogogue in mothers of preterm infants [5, 6]. It is also used tomanage heart diseases and eye problems as well as inflammations and dyspepsia [7, 8].
Pharmacological studies have shown that the extracts of the plant have antioxidant [9-11], anticarcinogenic , anti-inflammatory, antispasmodic and antidiuretic  properties. Others include antiulcer, antibacterial and antifungal properties . Recent studies indicate that it also has antinociceptive  as well as wound healing ability . Studies on the root bark have shown it to have analgesic, alexeteric, and antihelminthic properties. It has also been reported to alter blood lipid profiles . Toxicity studies have shown that aqueous extract of moringa leaf extract has no significant adverse effects in rats, rabbits [15-18] or poultry . However, there are significant differences in the safety and composition of various moringa species from different locations .
In Ghana and most parts ofWest Africa, powdered leaves of M. oleifera are marketed under different brand names and consumed daily as a nutraceutical, prophylaxis, or cure for various conditions. The prevailing socio-cultural/economic conditions and consequent difficulty in accessing healthcare services, especially by rural populations as well as the general perception that plant medicines are efficacious and free from side effects [19, 20] will increase the frequent and widespread spread use of moringa leaf powder. In view of the reported differences inmoringa leaf products, which may impact adversely on its safety, the micro- and macroelemental content of dried leaves of Moringa oleifera were measured. In addition, the leaf extract was investigated for its toxicological effects in Sprague-Dawley rats.
2. Materials and Methods
2.1. Preparation of Extracts of Moringa oleifera Leaves for Analysis. In order to mimic the traditional method of extraction, 2.8 kg of sample were blended with boiled distilled water. The mixture, covered with water, was left to stand overnight in a water bath maintained at 60[degrees]C and the watery portion (infusion) was filtered off using 0.45 [micro]m millipore cellulose ester filters and freeze dried to obtain M. oleifera extract (MOE). Portions were homogenized and labelled as sample A for elemental analysis.
2.2. Preparation of Moringa oleifera Leaves for Analysis. Leaves of the Moringa oleifera species were collected from Accra, separated from other plant parts, washed and dried in the shade for five days at room temperature, ground into fine powder, sieved (212 [micro]m mesh size) to obtain very fine samples, and kept in separate containers. This was labelled sample B.
2.3. Pelleting of Samples for Analysis. The loose/powdery nature of samples (plant extracts A and leaf powder B) required that they were pelleted before analysis. Before pelleting, 4 g of each sample was weighed and 0.9 g of the binder Fluxana (H Elektronic BM-0002-1 (Licowax C micropowder PM-Hoechstwax)) was added and homogenized for 3 minutes. The mixture was pressed at 20 t or 2 minutes into pellets of 32 mm in diameter for the subsequent XRF measurements. Three separate pellets were prepared from each of samples A and B.
2.4. Energy Dispersive X-Ray (ED XRF) Measurements. Energy dispersive X-ray (ED XRF) was used for simultaneous analysis and measurement of the elemental content of the samples. The procedure, which used three-axial geometry, reduced background noise due to radiation polarization. The monochromatic radiations emitted from the X-ray tube were applied to excite the atoms of the sample.
2.5. Experimental Animals and Housing Conditions. Male Sprague-Dawley rats (150 g-180 g body weight) were purchased from the Centre for Scientific Research into Plant Medicine, Mampong. The rats were housed in plastic cages with stainless steel tops in the animal care facility of the University of Ghana Medical School and kept under standard 12 h light and 12 h dark schedule where room temperature, humidity, and ventilation were controlled during the acclimatization period of seven (7) days.
2.6. Acute and Subacute Toxicity Studies. The reconstituted powdered MOE mixture was prepared using distilledwater as the vehicle and administered as a single dose (5,000 mg/kg) by oral gavage for the acute toxicity studies. After the administration, animals were observed every hour for the first 6 hours then daily for the next 13 days.
In the subacute studies, five groups (1-5) of male Sprague-Dawley Rats (eight weeks old, seven animals/group) of mean weight 150 g were prepared. Animals in each of the four groups were administered MOE extract over a dose range of 0 mg/kg to 1000/kg by oral gavage daily for 14 days. Animals in the fifth group received the vehicle (distilled water) and served as controls.
For the subacute studies, after the14 days of MOE administration of MOE, each animal was observed every hour for six hours daily for the next 3 days and subsequently every day for 10 days. Animals were fed ad libitum with standard chow diet (AIN-93G formulation obtained from GAFCO-Ghana).
2.6.1. Observed Clinical Signs of Toxidromes. Body weights were observed daily before and after administration. In addition, animals were observed daily for clinical signs of excitability, twitching, salivation, morbidity, miosis, mydriasis, rising fur, sluggish movement, draping, tremors, and so forth.
2.7. Laboratory Examinations
2.7.1. Blood Samples. Under chloroform anaesthesia, blood was obtained via cardiac puncture and the animals euthanized by exsanguinations. Samples of the blood collected were aliquoted into EDTA-2K tubes and plain tubes, respectively. The EDTA blood was immediately analysed for haematological parameters using the SYSMEX Haematology Autoanalyser [Kobe, Japan] while serum prepared from blood in the plain tubes was used for biochemical examinations.
2.8. Necropsy and Histopathological Studies. Gross pathological investigations were conducted on each animal following exsanguination. The heart, kidney, liver, and gastrointestinal tract were prepared for histopathological examinations. All experimental procedures and assays were conducted in accordance with the international guidelines for evaluating the safety of herbal medicines [21-23].
2.9. Statistical Analysis. Results are presented as means [+ or -] SEM and analysis for statistical differences was done using one-way ANOVA followed by Bonferroni post-hoc test. P values less than 0.05 were considered statistically significant.
The ED-XRF analyses led to the detection of a total of thirty-five (35) elements comprising eleven (11) major elements and twenty-four (24) minor elements. The major elements detected included Na, Mg, Al, Si, P, S, Cl, K, Ca, Mn, and Fe and other heavy metals. Tables 1 and 2 show details of the elements detected and their concentrations.
3.1. Clinical Symptoms. In the acute toxicity studies as well as the subacute studies at all the dose levels, grooming, repetitive circling with arched-back posture were observed in all the rats except those in the control group. Rats given high doses of MOE (1000 mg/kg and 5000 mg/kg) showed more excitability, twitching, and salivation. Necropsy revealed no abnormalities.
3.2. Haematology. These results of haematological investigations are presented in Table 3 (acute toxicity) and Table 4 (subacute toxicity studies). In the acute toxicity studies, WBC increased significantly (by 52.5%). MCV, on the other hand, decreased by 10%. Similarly, platelets levels dropped significantly (62.5%) following treatment with MOE.
In the subacute studies, WBC increased by 73.75% and 67% (P < 0.0001) at dose levels of 40 mg/kg and 80 mg/kg, respectively. MCV dropped significantly at the 200 mg/kg and 1000 mg/kg dose levels. Similarly, platelets levels rose significantly over baseline level at the 80 mg/kg dose level. However, at 1000 mg/kg, they dropped significantly.
3.3. Biochemical Analysis. Figure 1 shows results obtained from the biochemical parameters used as markers for renal function. The figure shows that blood urea levels were elevated at dose levels of 80 mg/kg and 1000 mg/kg. Creatinine levels, however, significantly decreased at all dose levels compared to the controls.
Figures 2 and 3 show results for the biochemical test for liver function and lipid profiles, respectively. There were increases in the levels of liver enzymes during MOE administration in a non-dose dependent manner. AST levels, however, reduced at all dose levels except the 80 mg/kg group. There were decreases in the lipid parameters during MOE administration. For the lipid profiles, MOE administration generally led to a decrease in total cholesterol and triglycerides as well as LDL and, to some extent, HDL cholesterol.
3.4. Histopathology. Photomicrographs of tissues prepared from control and animals treated with MOE at different dose levels are presented in Figures 5-8. No observable cardiomyopathy was noted in the heart (Figure 5). Figure 6 showed no observable ulceration. The epithelial cells of the stomach are intact. Figure 7 also showed no observable histological lesions in the glomerulus and the tubules. There were no observable histological lesions in the sinusoids and central vein of the liver (Figure 8).
Normally, herbal preparations are considered relatively safe and devoid of numerous adverse effects probably because they are considered to be "natural." This study attempted to analyse the elemental content of Moringa oleifera and to ascertain if a 14-day dosing could have any observable adverse effects. This is in view of the widespread use of moringa leaf powder as a food supplement and treatment for various disease conditions.
X-ray fluorescence (XRF) is a fast, accurate, and non-destructive analytical technique used for the elemental and chemical analysis of powdered, solid, and liquid samples. Analyses of the samples produced a total of 35 elements (14 macroelements and 21 microelements) in M. oleifera. The concentrations of macroelements in the powdered leaf samples are shown in Figure 4 and included S, Ca, K, Mg, Na, P, Si, Cl, Al, Fe, and Mn. The minor elements in the decreasing order were V, Ba, Cr, Y, Ba, Zn, Rb, Ce, La, Cu, Cs, Sn, Hf, Co, Ni, Nb, Ta, U, Mo, Pb, Bi, Ga, Th, As, and Zr. All concentrations were within the recommended daily allowance (RDA) limits. RDA, the average daily dietary intake level, is expected to be sufficient to meet the nutrient requirements of all healthy individuals [24-26]. These results, therefore, would suggest that consumption of moringa leaf powder can provide users with some of the essential minerals that the human body requires for optimum function.
Blood parameter analysis is relevant to risk evaluation as the haematological system has a higher predictive value for toxicity in humans (91%) . Moringa oleifera extract administration was accompanied by a reduction in the haematopoietic system (Tables 3 and 4) at a dosage of 40 mg/kg which is evidenced by the levels of RBC, HCT, HGB, WBC, and lymphocytes. The slightly reduced HGB, HCT, RBC, and total protein in the rats suggest potential interference with the haematopoietic system that would require further investigations. The high RBC could also be due to hypoxic conditions that might have resulted due to the high doses ofMOE administered. The absence of a major significant change in haematological parameters is consistent with observations by Awodele et al. .
The statistically significant increase in lymphocytes at MOE doses of 40-80 mg/kg and the 5,000 mg/kg BW in the animals might suggest the presence of infection/stress or a potential immune boosting effect of MOE at the stated dose levels. Since the animals were specific pathogen-free and were kept in a barrier system, the observed effects are likely to be due to potential immune boosting effects of the extract [13, 14, 28]. This needs further investigation in a subchronic or chronic study.
AST, ALT, and ALP are major markers of liver function. Toxic injury to the liver leads to elevation in levels of all these liver enzymes.Thus, the observed rise in ALT and ALP following administration of MOE (Tables 5 and 6) would suggest a potential adverse effect of MOE on the liver. Since ALT is localized primarily in the cytosol of hepatocytes, it is a more sensitive marker of hepatocellular damage than AST and ALP [27, 28]. Withinlimits, these can provide a quantitative assessment of the degree of damage sustained by the liver. Histopathological examinations, however, did not reveal anyhistological lesionsin the sinusoids or central vein (Figure 8).
The copper component in the extract (Table 2) which is a component of a number of enzymes that are involved in reducing molecular oxygen, metabolizing substances such as histamine, serotonin, epinephrine, norepinephrine, and dopamine could pose a threat during abnormal consumption of the extract. Copper deficiency, although rare, results in hypochromic anaemia ; possible side-effects may include liver damage and Wilson's syndrome.
Direct, indirect, and total bilirubin reflects the liver's ability to take up, process, and secrete bilirubin into bile and can also be considered as a true test of liver function [27, 28]. These were all high at the different doses, especially at the 5,000 mg/kg single oral high dose compared to the controls (Tables 5 and 6). However, total protein, globulin, and albumin remained relatively unchanged or slightly increased in all the groups in comparison with the controls. These were not entirely dose dependent and significant but require further monitoring in subchronic studies.
It must also be noted that gross pathological examination of the treated animals did not reveal any abnormalities such as presence of lesions or changes in colour of internal organs and relative organ weights as compared to the controls.
The kidneys are concerned with the elimination of drugs from the body and are likely to be affected during such toxicity studies at high doses. In the treated male rats, creatinine levels were reduced compared to the controls (P < 0.05) while urea levels were inconsistent among the groups. This suggests that MOE did not adversely affect the integrity of the renal system . Also, histopathological examinations did not reveal any observable histological lesions in the glomeruli and the tubules (Figure 7). However, the reduction in creatinine levels may be deemed to be positive effect of MOE on the renal system, which could be exploited therapeutically. These findings are consistent with those reported by Isitua and Ibeh, 2013 .
Ingestion of chemicals substances including those of plant origin in excess and especially over long periods may adversely affect major organs like the heart, kidney, liver, and even the gastrointestinal system. Thus, the evaluation of histopathological changes in organs remains a cornerstone in assessing the safety of medicines and other substances [30, 31]. Histopathological examinations of the heart and stomach did not reveal any observable cardiomyopathies (Figure 5) and ulcerations of the epithelial cells in the male rats (Figure 6). These findings are consistent with other studies . It might be expected that at high doses of MOE may result in accumulation of MOE-derived iron. This mineral, though an important component of haemoglobin and other proteins and enzymes, may cause gastrointestinal distress, hemochromatosis, and so forth [22, 23]. The absence of these effects may be explained by the fact that the various elements were within normal limits .
It is important to note that the effects of chemicals produced in laboratory animals when properly conducted provide a useful indication of safety in humans . Thus, from the above results, it would be expedient to conduct subchronic or chronic toxicity studies with regard to the hematopoietic, renal, hepatic, and reproductive changes because MOE is used as a food supplement and is used over a long period of time by consumers. Moreover, the contamination of moringa leaves by heavy metals like lead (Pb) and arsenic (As) may pose a threat to humans because they are not biodegradable. With reference to the RDA limits and other studies conducted regarding the presence of heavy metals in the leaves of MOE [34, 35], it is imperative that prevention of any possible cumulative toxicity of some of the elements is most desirable during prolonged use of MOE. There is, thus, the need for toxicological studies to be conducted on moringa from different locations in order to give an indication of their comparative safety.
It must, however, be stated that, because plants may absorb elements from the soil and environment, some of which may be toxic to humans, plant nutrition, climate, and soil conditions and locations could also determine the elemental contents in the leaves [19, 34, 35].
This study has provided some evidence that Moringa oleifera that was collected in Accra, Ghana, in West Africa is reasonably safe for consumption taking into account the elemental composition when administered to rats. The acute studies showed that the median lethal dose ([LD.sub.50]) could be greater than 5000 mg/kg as all the animals survived at his dose level. It is also important to monitor the concentration of its elemental composition as a possible reason of serious health alterations.
Based on the levels of these minerals and the permissible amount in the human body, it is recommended that the consumption of Moringa oleifera leaves be limited to a maximum of 70 grams per day in order to prevent excessive consumption and subsequent accumulation of some of these essential elements. At 70 grams per day, most of these elements in the leaves could be found in high quantities approaching the RDA limit.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors' appreciation goes to Dr. Daniel Boamah and his staff at the geochemistry department of the Ghana geological survey department for the assistance and usage of their EDXRF equipment.
 P. F. Raguindin, L. F. Dans, and J. F. King, "Moringa oleifera as a Galactagogue," BreastfeedingMedicine, vol. 9, pp. 323-324, 2014.
 M. K. Titi, E. T. Harijono, and S. W. Endang, "Effect lactagogue moringa leaves (Moringa oleifera Lam) powder in rats white female wistar," Journal of Basic and Applied Scientific Research, vol. 3, no. 4, pp. 430-434, 2013.
 J. W. Fahey, "A review of the medical evidence for its nutritional, therapeutic, and prophylactic properties. Part 1," Trees for Life Journal, vol. 1, pp. 5-15, 2005.
 S. Wadhwa, M. S. Panwar, N. Saini, S. S. Rawat, and S. Singhal, "A review on commercial, traditional uses, phytoconstituents and pharmacological activity of Moringa oleifera," Global Journal of Traditional Medicinal Systems, vol. 2, no. 1, pp. 1-13, 2013.
 Trees for Life (TFL), Moringa Book, 2005, http://www.treeforlife.org.
 A. H. Mollik, "Plants from Sundarbans to the diet of lactating mothers during puerperium of Barguna district of Bangladesh," Pediatric Nephrology, vol. 25, article 1904, abstract #298, 2010.
 M. R. Sulaiman, Z. A. Zakaria, A. S. Bujarimin, M. N. Somchit, D. A. Israf, and S. Moin, "Evaluation of moringa oleifera aqueous extract for antinociceptive and anti-inflammatory activities in animal models," Pharmaceutical Biology, vol. 46, no. 12, pp. 838-845, 2008.
 B. S. Rathi, S. L. Bodhankar, and A. M. Baheti, "Evaluation of aqueous leaves extract of Moringa oleifera Linn for wound healing in albino rats," Indian Journal of Experimental Biology, vol. 44, no. 11, pp. 898-901, 2006.
 S. Luqman, S. Srivastava, R. Kumar, A. K. Maurya, and D. Chanda, "Experimental assessment of Moringa oleifera leaf and fruit for its antistress, antioxidant, and scavenging potential using in vitro and in vivo assays," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 519084, 12 pages, 2012.
 S. Luqman and R. Kumar, "Attenuation of hydroxyl radical formation by extracted constituent of moringa oleifera lam," Current Chemical Biology, vol. 5, no. 3, pp. 213-218, 2011.
 A. R. Verma, M. Vijayakumar, C. S. Mathela, and C. V. Rao, "In vitro and in vivo antioxidant properties of different fractions of Moringa oleifera leaves," Food and Chemical Toxicology, vol. 47, no. 9, pp. 2196-2201, 2009.
 I. L. Jung, "Soluble extract from Moringa oleifera leaves with a new anticancer activity," PLoS ONE, vol. 9, no. 4, 2014.
 D. K. Dubey, J. Dora, A. Kumar, and R. K. Gulsan, "A multipurpose tree--Moringa oleifera," International Journal of Pharmaceutical and Chemical Sciences, vol. 5, no. 2, pp. 102-105, 2014.
 J. Mehta, A. Shukla, V. Bukhariya, and R. Charde, "The magic remedy of Moringa oleifera: an overview," International Journal of Biomedical and Advance Research, vol. 2, no. 5, pp. 215-227, 2011.
 A. A. Adedapo, O. M. Mogbojuri, and B. O. Emikpe, "Safety evaluations of the aqueous extract of the leaves of Moringa oleifera in rats," Journal of Medicinal Plants Research, vol. 3, no. 8, pp. 586-591, 2009.
 O. Awodele, I. A. Oreagba, S. Odoma, J. A. Teixeira Da Silva, and V. O. Osunkalu, "Toxicological evaluation of the aqueous leaf extract of Moringa oleifera Lam. (Moringaceae)," Journal of Ethnopharmacology, vol. 139, no. 2, pp. 330-336, 2012.
 C. C. Isitua and I.N. Ibeh, "Toxicological assessment of aqueous extract of Moringa oleifera and Caulis bambusae leaves in rabbits," Journal of Clinical Toxicology, supplement 12, article 003, 2013.
 J. O. Ashong and D. L. Brown, "Safety and efficacy of Moringa oleifera powder for growing poultry," Journal of Animal Science, vol. 89, E-supplement 1, p. 84, 2011.
 K. Freer, Exposing the Lies and Deception Behind Organic Moringa oleifera Leaf Powder Not All Moringa Oleifera Products Are Created Equal. You Might Be Shocked at the Truth Kate Freer, Yahoo Contributor Network, 2010.
 D. Jaiswal, P. K. Rai, S. Mehta et al., "Role of Moringa oleifera in regulation of diabetes-induced oxidative stress," Asian Pacific Journal of Tropical Medicine, vol. 6, no. 6, pp. 426-432, 2013.
 World Health Organization, Quality Control Methods for Medicinal Plant Materials, WHO Offset Publication, WHO, Geneva, Switzerland, 1998.
 WHO, Guidelines for the Assessment of Herbal Medicines WHO/TRM/91.4, WHO, Geneva, Switzerland, 1991.
 Organization for Economic Cooperation and Development (OECD) Guidelines, OECD Guidelines for Testing of Chemicals: Acute Oral Toxicity-Fixed Dose Procedure, 420, 2001.
 R. E. Lopez de Ruiz, R. A. Olsina, and A. N. Masi, "Different analytical methodologies for the preconcentration and determination of trace chromium by XRF in medicinal herbs with effects on metabolism," X-Ray Spectrometry, vol. 31, no. 2, pp. 150-153, 2002.
 M. J. Anjos, R. T. Lopes, E. F. O. Jesus, S. M. Simabuco, and R. Cesareo, "Quantitative determination of metals in radish using x-ray fluorescence spectrometry," X-Ray Spectrometry, vol. 31, no. 2, pp. 120-123, 2002.
 C. Vazquez, N. Barbara, and S. Lopez, "XRF analysis of micronutrients in endive grown on soils with sewage sludge," X-Ray Spectrometry, vol. 32, no. 1, pp. 57-59, 2003.
 Taconic Technical Library. Hematological Clinical Chemistry values Sprague-Dawley Rats, 2003.
 C. K. Janeway, "Immunobiology," in The Immune System in Health and Disease, E. Lawrence, Ed., pp. 461-463, Garland Science, New York, NY, USA, 6th edition, 2005.
 W. Arneson and J. Brickell, "Assessment of liver function," in Clinical Chemistry: A Laboratory Perspective, pp. 233-266,Davis Davis Company, Philadelphia, Pa, USA, 1st edition, 2007.
 S. K. Ramaiah, "A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters," Food and Chemical Toxicology, vol. 45, no. 9, pp. 1551-1557, 2007.
 P. Greaves, Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation, Academic Press, New York, NY, USA, 3rd edition, 2007.
 P. I. Zvinorova, L. Lekhanya, K. Erlwanger, and E. Chivandi, "Dietary effects of Moringa oleifera leaf powder on growth, gastrointestinal morphometry and blood and liver metabolites in Sprague-Dawley rats," Journal of Animal Physiology and Animal Nutrition, 2014.
 H. Olson, G. Betton, D. Robinsdon et al., "Concordance of toxicity of pharmaceuticals in humans and in animals," Regulatory Toxicology and Pharmacology, vol. 32, pp. 56-67, 2000.
 C. Limmatvapirat, S. Limmatvapirat, J. Charoenteeraboon, and T. Phaechamud, "Inductively coupled plasma mass spectrometric determination of heavy metals in Moringa oleifera Lam. leaves," Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 4, no. 1, pp. 161-168, 2013.
 K. Annan, R. Dickson, I. Amponsah, and I. Nooni, "The heavy metal contents of some selected medicinal plants sampled from different geographical locations," Pharmacognosy Research, vol. 5, no. 2, pp. 103-108, 2013.
I. J. Asiedu-Gyekye, (1) S. Frimpong-Manso, (2) C. Awortwe, (3) D. A. Antwi,(4) and A. K. Nyarko (1)
(1) Department of Pharmacology and Toxicology, College of Health Sciences, University of Ghana School of Pharmacy, P.O. Box LG 43, Legon, Ghana
(2) Department of Pharmaceutical Chemistry, College of Health Sciences, University of Ghana School of Pharmacy, P.O. Box LG 43, Legon, Ghana
(3) Division of Clinical Pharmacology, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, Cape Town, South Africa
(4) Department of Physiology, College of Health Sciences, University of Ghana Medical School, P.O. Box 4236, Korle-Bu, Ghana
Correspondence should be addressed to I. J. Asiedu-Gyekye; firstname.lastname@example.org
Received 6 February 2014; Revised 25 June 2014; Accepted 25 June 2014; Published 22 July 2014
Academic Editor: Margaret James
Copyright [c] 2014 I. J. Asiedu-Gyekye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
TABLE 1: Concentrations of major oxides per totalmass of powdered leaf in milligrams. Major oxides Level in sample (mg) [Na.sub.2]O 37.5 MgO 60.6 [Al.sub.2][O.sub.3] 13.0 [SiO.sub.2] 30.0 [P.sub.2][O.sub.5] 37.0 [SO.sub.3] 122.8 CI 17.6 [K.sub.2]O 78.4 CaO 118.0 MnO 0.4 [Fe.sub.2][O.sub.3] 3.0 TABLE 2: Concentrations of minor elements per total mass of powdered leaf in milligrams. Minor elements Level in sample (mg) V 2.400 Cr 0.578 Co 0.012 Ni 0.0148 Cu 0.0318 Zn 0.1156 Ga 0.0032 As 0.0022 Rb 0.0758 Y 0.3542 Zr 0.0024 Nb 0.0116 Mo 0.0056 Sn 0.0576 Cs 0.0242 Ba 0.8900 La 0.0490 Ce 0.0694 Hf 0.0154 Ta 0.0114 Pb 0.0044 Th 0.0032 TABLE 3: Haematological analysis of a 5,000mg/kg single dose administration of MOE inmale SDRs. Values are expressed as mean [+ or -] SEM (n = 7). Values of P < 0.05 were considered as statistically significant. *P < 0.05, (**) P < 0.01, and (***) P < 0.0001 when control was compared with MOE. Groups Parameters Control males WBC ([10.sup.3] [micro]L) 4.8 [+ or -] 0.32 RBC ([10.sup.6][micro]L) 8.3 [+ or -] 0.40 HGB (g/dL) 15.1 [+ or -] 0.59 HCT (%) 53.6 [+ or -] 2.31 MCV (fl) 65 [+ or -] 0.38 MCH (pg) 18.3 [+ or -] 0.16 MCHC (g/dL) 28.17 [+ or -] 0.16 PLT ([10.sup.3] [micro]L) 300.3 [+ or -] 44.44 LYM% 84.33 [+ or -] 1.39 LYM number 4.1 [+ or -] 0.28 Groups Parameters 5000 mg/kg males WBC ([10.sup.3] [micro]L) 7.32 [+ or -] 0.04 (***) RBC ([10.sup.6][micro]L) 8.84 [+ or -] 0.04 HGB (g/dL) 14.82 [+ or -] 0.04 HCT (%) 52 [+ or -] 0.32 MCV (fl) 58.2 [+ or -] 0.07 (***) MCH (pg) 16.64 [+ or -] 0.04 MCHC (g/dL) 28.6 [+ or -] 0.04 PLT ([10.sup.3] [micro]L) 112.8 [+ or -] 0.37 (**) LYM% 83.14 [+ or -] 0.05 LYM number 6.1 [+ or -] 0.04 TABLE 4: Haematological Analysis of a 14-day administration of MOE in male SDRs. Values are expressed as mean [+ or -] SEM (n = 7). Values of P < 0.05 were considered as statistically significant. (*) P < 0.05, (**) P < 0.01, and (***) P < 0.0001 when control was compared with MOE. Groups Parameters Control males WBC ([10.sup.3][micro]L) 4.8 [+ or -] 0.32 RBC ([10.sup.6] [micro]L) 8.3 [+ or -] 0.40 HGB (g/dL) 15.1 [+ or -] 0.59 HCT (%) 53.6 [+ or -] 2.31 MCV (fL) 65 [+ or -] 0.38 MCH (pg) 18.3 [+ or -] 0.16 MCHC (g/dL) 28.17 [+ or -] 0.16 PLT ([10.sup.3] [micro] L) 300.3 [+ or -] 44.44 LYM% 84.33 [+ or -] 1.39 LYM number 4.1 [+ or -] 0.28 Groups Parameters 40 mg/kg males WBC ([10.sup.3][micro]L) 8.34 [+ or -] 0.02 (***) RBC ([10.sup.6] [micro]L) 6.06 [+ or -] 0.08 (***) HGB (g/dL) 10.7 [+ or -] 0.04 HCT (%) 39 [+ or -] 0.49 MCV (fL) 65.14 [+ or -] 0.22 MCH (pg) 18.66 [+ or -] 0.02 MCHC (g/dL) 28.36 [+ or -] 0.02 PLT ([10.sup.3] [micro] L) 377 [+ or -] 20.87 LYM% 75.8 [+ or -] 0.04 LYM number 6.34 [+ or -] 0.05 Groups Parameters 80 mg/kg males WBC ([10.sup.3][micro]L) 7.2 [+ or -] 0.03 (***) RBC ([10.sup.6] [micro]L) 6.55 [+ or -] 0.49 (*) HGB (g/dL) 13.75 [+ or -] 0.08 HCT (%) 41.2 [+ or -] 3.25 MCV (fL) 62.78 [+ or -] 0.73 (*) MCH (pg) 18.5 [+ or -] 0.09 MCHC (g/dL) 29.25 [+ or -] 0.17 PLT ([10.sup.3] [micro] L) 577.2 [+ or -] 45.78 (***) LYM% 60.02 [+ or -] 6.32 (*) LYM number 8.9 [+ or -] 0.98 Groups Parameters 200 mg/kg males WBC ([10.sup.3][micro]L) 4.2 [+ or -] 0.32 RBC ([10.sup.6] [micro]L) 7.71 [+ or -] 0.04 HGB (g/dL) 13.74 [+ or -] 0.04 HCT (%) 46.22 [+ or -] 0.75 MCV (fL) 61.27 [+ or -] 0.16 (***) MCH (pg) 17.74 [+ or -] 0.07 MCHC (g/dL) 28.6 [+ or -] 0.24 PLT ([10.sup.3] [micro] L) 311.2 [+ or -] 3.96 LYM% 82.42 [+ or -] 0.59 LYM number 3.36 [+ or -] 0.24 Groups Parameters 1000 mg/kg males P value WBC ([10.sup.3][micro]L) 4.6 [+ or -] 0.14 0.0001 RBC ([10.sup.6] [micro]L) 7.64 [+ or -] 0.19 0.0001 HGB (g/dL) 12.8 [+ or -] 0.66 0.934 HCT (%) 46.8 [+ or -] 1.71 0.0451 MCV (fL) 61.1 [+ or -] 0.66 (***) 0.0001 MCH (pg) 16.73 [+ or -] 0.61 0.9705 MCHC (g/dL) 27.32 [+ or -] 0.93 0.9846 PLT ([10.sup.3] [micro] L) 137 [+ or -] 13.09 (**) 0.0001 LYM% 84.42 [+ or -] 0.97 0.0098 LYM number 3.78 [+ or -] 0.04 0.9535 TABLE 5 Groups Parameters Control males 5000 mg/kg males Urea 5.3 [+ or -] 0.18 5.83 [+ or -] 0.8 Creatinine 74.7 [+ or -] 3.07 27.14 [+ or -] 0.87 (***) T. protein 59.96 [+ or -] 1.44 67.5 [+ or -] 2.90 Albumin 35 [+ or -] 0.31 36.08 [+ or -] 0.99 Globulin 24.66 [+ or -] 1.46 31.16 [+ or -] 2.3 Dir. Bil. 2.02 [+ or -] 0.16 5.42 [+ or -] 1.00 (***) Indirct. Bil. 1.5 [+ or -] 0.29 2.72 [+ or -] 0.59 T. Bil. 3.44 [+ or -] 0.29 6.16 [+ or -] 1.14 (*) ALT 52.28 [+ or -] 0.29 113.5 [+ or -] 7.19 AST 190.1 [+ or -] 4.96 224.4 [+ or -] 53.89 ALP 151.2 [+ or -] 0.196 276.9 [+ or -] 0.045 (***) Cholesterol 5.69 [+ or -] 0.2 4.18 [+ or -] 0.01 (***) Trig. 0.87 [+ or -] 0.01 0.4 [+ or -] 0.003 (***) LDL 4.02 [+ or -] 0.04 3.11 [+ or -] 0.004 (***) HDL 1.30 [+ or -] 0.01 0.88 [+ or -] 0.01 These are statistical significance: (*) P < 0.05; ** P < 0.01; (***) P < 0.0001. TABLE 6 Groups Parameters Control males 1000 mg/kg males Urea 5.3 [+ or -] 0.18 6.13 [+ or -] 0.52 Creatinine 74.7 [+ or -] 3.07 39.66 [+ or -] 13.23 (*) T. protein 59.96 [+ or -] 1.44 61.52 [+ or -] 2.68 Albumin 35 [+ or -] 0.31 40.56 [+ or -] 2.24 (*) Globulin 24.66 [+ or -] 1.46 23.64 [+ or -] 2.60 Dir. bil. 2.02 [+ or -] 0.16 4.12 [+ or -] 0.26 Indirdt. bil. 1.5 [+ or -] 0.29 0.92 [+ or -] 0.07 T. bil. 3.44 [+ or -] 0.3 4.9 [+ or -] 0.30 ALT 52.28 [+ or -] 0.29 109.8 [+ or -] 9.06 AST 190.1 [+ or -] 4.96 397.5 [+ or -] 0.04 ALP 151.2 [+ or -] 0.196 106.0 [+ or -] 0.049 (***) Cholesterol 5.69 [+ or -] 0.2 3.86 [+ or -] 0.02 (***) Trig. 0.87 [+ or -] 0.01 0.4 [+ or -] 0.01 (***) LDL 4.02 [+ or -] 0.04 2.49 [+ or -] 0.01 HDL 1.30 [+ or -] 0.01 1.20 [+ or -] 0.01 Groups Parameters 200 mg/kg males 80 mg/kg males Urea 5.01 [+ or -] 0.27 8.34 [+ or -] 0.27 Creatinine 52.4 [+ or -] 4.03 61.04 [+ or -] 3.84 T. protein 61.82 [+ or -] 1.38 60.92 [+ or -] 1.26 Albumin 36.92 [+ or -] 0.75 32.12 [+ or -] 0.66 Globulin 25.1 [+ or -] 1.71 28.80 [+ or -] 0.91 Dir. bil. 2.92 [+ or -] 0.37 2.68 [+ or -] 0.28 Indirdt. bil. 1.9 [+ or -] 0.35 1.46 [+ or -] 0.06 T. bil. 4.64 [+ or -] 0.21 3.92 [+ or -] 0.07 ALT 93.92 [+ or -] 2.93 131.3 [+ or -] 25.29 (**) AST 364.5 [+ or -] 22.21 337.3 [+ or -] 112.4 ALP 103.1 [+ or -] 0.04 (***) 165.1 [+ or -] 0.037 (***) Cholesterol 5.28 [+ or -] 0.04 (***) 4.39 [+ or -] 0.005 (***) Trig. 0.4 [+ or -] 0.01 (***) 0.69 [+ or -] 0.01 (***) LDL 3.78 [+ or -] 0.01 3.19 [+ or -] 0.004 HDL 1.22 [+ or -] 0.01 0.88 [+ or -] 0.01 Groups Parameters 40 mg/kg males P value Urea 5.59 [+ or -] 0.49 0.2143 Creatinine 37.52 [+ or -] 7.27 (**) 0.0005 T. protein 65.84 [+ or -] 1.98 0.0913 Albumin 37.7 [+ or -] 1.23 0.0016 Globulin 51.74 [+ or -] 6.83 (***) 0.0001 Dir. bil. 2.98 [+ or -] 0.05 0.0004 Indirdt. bil. 1.74 [+ or -] 0.02 0.0120 T. bil. 4.34 [+ or -] 0.22 0.0188 ALT 77.98 [+ or -] 16.67 0.0049 AST 253.3 [+ or -] 78.91 0.1928 ALP 95.84 [+ or -] 0.051 (***) 0.0001 Cholesterol 4.23 [+ or -] 0.10 (***) 0.0001 Trig. 0.38 [+ or -] 0.01 (***) 0.0001 LDL 0.8 [+ or -] 0.005 0.0001 HDL 0.98 [+ or -] 0.01 0.0001 These are statistical significance: (*) P < 0.05; (**) P < 0.01; (***) P < 0.0001.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Research Article|
|Author:||Asiedu-Gyekye, I.J.; Frimpong-Manso, S.; Awortwe, C.; Antwi, D.A.; Nyarko, A.K.|
|Publication:||Journal of Toxicology|
|Date:||Jan 1, 2014|
|Previous Article:||Botulinum toxin suppression of CNS network activity in vitro.|
|Next Article:||Resveratrol sensitizes selectively thyroid cancer cell to 131-iodine toxicity.|